Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Publications Fischer Dirk

Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial

Putananickal N.; Gross E.C.; Orsini A.-L.; Schmidt S.; Hafner P.; Gocheva V.; Nagy S.; Henzi B.C.; Rubino D.; Vogt D.R.; Cichon S.; Sandor P.; Fischer D.. Cephalalgia : an international journal of headache. 2022.

Implementation of Motor Function Measure score percentile curves - Predicting motor function loss in Duchenne muscular dystrophy.

Hafner P; Schmidt S; Schädelin S; Rippert P; Hamroun D; Fabien S; Henzi B; Putananickal N; Rubino-Nacht D; Vuillerot C; Fischer D; MFM registry Study Group. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2022.

Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome

Wendebourg M.J.; Weigel M.; Richter L.; Gocheva V.; Hafner P.; Orsini A.-L.; Crepulja V.; Schmidt S.; Huck A.; Oechtering J.; Blatow M.; Haas T.; Granziera C.; Kappos L.; Cattin P.; Bieri O.; Fischer D.; Schlaeger R.. European journal of neurology. 2022.

Stable-Isotope Dilution GC-MS Measurement of Metformin in Human Serum and Urine after Derivatization with Pentafluoropropionic Anhydride and Its Application in Becker Muscular Dystrophy Patients Administered with Metformin, l-Citrulline, or Their Combination.

Baskal S; Bollenbach A; Henzi B; Hafner P; Fischer D; Tsikas D. Molecules (Basel, Switzerland). 2022.

Mitochondrial function and oxidative stress markers in higher-frequency episodic migraine.

Gross EC; Putananickal N; Orsini AL; Vogt DR; Sandor PS; Schoenen J; Fischer D. Scientific Reports. 2021.

Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?

Kourakis S; Timpani CA; Campelj DG; Hafner P; Gueven N; Fischer D; Rybalka E. Orphanet Journal of Rare Diseases. 2021.

Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy

Kourakis S.; Timpani C.A.; de Haan J.B.; Gueven N.; Fischer D.; Rybalka E.. Redox Biology. 2021.

Treatment with L-Citrulline in patients with post-polio syndrome: A single center, randomized, double blind, placebo-controlled trial.

Putananickal N; Orsini AL; Schmidt S; Gocheva V; Rubino D; Haas T; Schädelin S; Deligianni X; Bieri O; Fischer D; Hafner P. Neuromuscular Disorders. 2021.

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?

Kourakis S; Timpani CA; de Haan JB; Gueven N; Fischer D; Rybalka E. Pharmaceuticals (Basel, Switzerland). 2020.

Health-related quality of life, self-reported impairments and activities of daily living in relation to muscle function in post-polio syndrome.

Gocheva V; Hafner P; Orsini AL; Schmidt S; Schaedelin S; Rueedi N; Rubino-Nacht D; Weber P; Fischer D. Journal of patient-reported outcomes. 2020.

Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy.

Nagy S; Schädelin S; Hafner P; Bonati U; Scherrer D; Ebi S; Schmidt S; Orsini AL; Bieri O; Fischer D. Muscle and Nerve. 2020.

Association Between Health-Related Quality of Life and Motor Function in Ambulant and Nonambulant Duchenne Muscular Dystrophy Patients.

Gocheva V; Schmidt S; Orsini AL; Hafner P; Schaedelin S; Rueedi N; Weber P; Fischer D. JOURNAL OF CHILD NEUROLOGY. 2019.

Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.

Hafner P; Bonati U; Klein A; Rubino D; Gocheva V; Schmidt S; Schroeder J; Bernert G; Laugel V; Steinlin M; Capone A; Gloor M; Bieri O; Hemkens LG; Speich B; Zumbrunn T; Gueven N; Fischer D. JAMA Network Open. 2019.

Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.

Gross E; Putananickal N; Orsini AL; Schmidt S; Vogt DR; Cichon S; Sandor P; Fischer D. Trials. 2019.

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy.

Nagy S; Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Bieri O; Vuillerot C; Bonati U; Fischer D. Journal of Visualized Experiments. 2019.

Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention.

Gross EC; Klement RJ; Schoenen J; D'Agostino DP; Fischer D. Nutrients. 2019.

Psychosocial adjustment and parental stress in Duchenne Muscular Dystrophy.

Gocheva V; Schmidt S; Orsini AL; Hafner P; Schaedelin S; Weber P; Fischer D. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2019.

Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.

Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D. Trials. 2019.

The metabolic face of migraine - from pathophysiology to treatment.

Gross EC; Lisicki M; Fischer D; Sándor PS; Schoenen J. Nature reviews. Neurology. 2019.

The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.

Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O. Neuromuscular Disorders. 2019.

An Objective and Child-friendly Assessment of Arm Function by Using a 3-D Sensor.

Chen X; Wolf D; Siebourg-Polster J; Czech C; Bonati U; Fischer D; Khwaja O; Strahm M. Journal of Visualized Experiments. 2018.

Effects of single and combined metformin and L-citrulline supplementation on L-arginine-related pathways in Becker muscular dystrophy patients: possible biochemical and clinical implications.

Hanff E; Hafner P; Bollenbach A; Bonati U; Kayacelebi AA; Fischer D; Tsikas D. AMINO ACIDS. 2018.

Reliable and fast volumetry of the lumbar spinal cord using cord image analyser (Cordial).

Tsagkas C; Altermatt A; Bonati U; Pezold S; Reinhard J; Amann M; Cattin P; Wuerfel J; Fischer D; Parmar K; Fischmann A. European radiology. 2018.

Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis.

Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Schroeder J; Naduvilekoot Devasia A; Zuesli S; Bernert G; Laugel V; Bloetzer C; Steinlin M; Capone A; Gloor M; Tobler P; Haas T; Bieri O; Zumbrunn T; Fischer D; Bonati U. Neuromuscular Disorders. 2018.

[Imaging of primary muscular diseases : What do neurologists expect from radiologists?].

Wattjes MP; Fischmann A; Fischer D. Radiologe. 2017.

A series of case reports from JEWELFISH, an open-label study to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of RG7916 in adult and pediatric patients with spinal muscular atrophy who previously participated in a study with another SMN2-targeting therapy

Chiriboga, C.; Mercuri, E.; Fischer, D.; Marquet, A.; Kraus, D.; Alexander, M.; Cho, A.; Armstrong, G.; Kletzl, H.; Czech, C.; Seabrook, T.; Abdallah, H.; Mueller, L.; Gorni, K.; Khwaja, O.. Neuromuscular Disorders. 2017.

Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.

Chen X; Siebourg-Polster J; Wolf D; Czech C; Bonati U; Fischer D; Khwaja O; Strahm M. PLoS One. 2017.

Frequent genes in rare diseases: panel-based next generation sequencing to disclose causal mutations in hereditary neuropathies.

Dohrn MF; Glöckle N; Mulahasanovic L; Heller C; Mohr J; Bauer C; Riesch E; Becker A; Battke F; Hörtnagel K; Hornemann T; Suriyanarayanan S; Blankenburg M; Schulz JB; Claeys KG; Gess B; Katona I; Ferbert A; Vittore D; Grimm A; Wolking S; Schöls L; Lerche H; Korenke GC; Fischer D; Schrank B; Kotzaeridou U; Kurlemann G; Dräger B; Schirmacher A; Young P; Schlotter-Weigel B; Biskup S. Journal of neurochemistry. 2017.

Longitudinal characterization of biomarkers for spinal muscular atrophy.

Bonati U; Holiga Š; Hellbach N; Risterucci C; Bergauer T; Tang W; Hafner P; Thoeni A; Bieri O; Gerlach I; Marquet A; Khwaja O; Sambataro F; Bertolino A; Dukart J; Fischmann A; Fischer D; Czech C. Annals of Clinical and Translational Neurology. 2017.

Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy.

Burakiewicz J; Sinclair CDJ; Fischer D; Walter GA; Kan HE; Hollingsworth KG. Journal of Neurology. 2017.

Treatment with L-citrulline in patients with post-polio syndrome: study protocol for a single-center, randomised, placebo-controlled, double-blind trial.

Schmidt S; Gocheva V; Zumbrunn T; Rubino-Nacht D; Bonati U; Fischer D; Hafner P. Trials. 2017.

Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.

Hafner P; Bonati U; Erne B; Schmid M; Rubino D; Pohlman U; Peters T; Rutz E; Frank S; Neuhaus C; Deuster S; Gloor M; Bieri O; Fischmann A; Sinnreich M; Gueven N; Fischer D. PLoS One. 2016.

Recent developments in muscle imaging of neuromuscular disorders.

Fischer D; Bonati U; Wattjes MP. Current Opinion in Neurology. 2016.

Recent developments in muscle imaging of neuromuscular disorders.

Fischer D; Bonati U; Wattjes MP. Current Opinion in Neurology. 2016.

The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study

Fischer D.; Hafner P.; Rubino D.; Schmid M.; Neuhaus C.; Jung H.; Bieri O.; Haas T.; Gloor M.; Fischmann A.; Bonati U.. Neuromuscular Disorders. 2016.

Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.

Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D. Trials. 2016.

Ultrasonographic reference values for peripheral nerves and nerve roots in the normal population of children and adolescents: study protocol for an observational-prospective trial.

Rasenack M; Décard BF; Schädelin S; Grimm A; Fischer D; Hafner P. BMJ Open. 2016.

Dysferlinopathy in Switzerland: clinical phenotypes and potential founder effects.

Petersen JA; Kuntzer T; Fischer D; von der Hagen M; Huebner A; Kana V; Lobrinus JA; Kress W; Rushing EJ; Sinnreich M; Jung HH. BMC neurology. 2015.

Longitudinal 2-point dixon muscle magnetic resonance imaging in becker muscular dystrophy

Bonati U.; Schmid M.; Hafner P.; Haas T.; Bieri O.; Gloor M.; Fischmann A.; Fischer D.. Muscle & Nerve. 2015.

Nerve ultrasound in Miller Fisher variant of Guillain-Barré syndrome.

Décard BF; Fladt J; Axer H; Fischer D; Grimm A. Muscle and Nerve. 2015.

Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy.

Bonati U; Hafner P; Schädelin S; Schmid M; Naduvilekoot Devasia A; Schroeder J; Zuesli S; Pohlman U; Neuhaus C; Klein A; Sinnreich M; Haas T; Gloor M; Bieri O; Fischmann A; Fischer D. Neuromuscular Disorders. 2015.

A novel missense mutation confirms ATL3 as a gene for hereditary sensory neuropathy type 1.

Fischer D; Schabhüttl M; Wieland T; Windhager R; Strom TM; Auer-Grumbach M. Brain : a journal of neurology. 2014.

Congenital muscular dystrophy with dropped head phenotype and cognitive impairment due to a novel mutation in the LMNA gene.

Bonati U; Bechtel N; Heinimann K; Rutz E; Schneider J; Frank S; Weber P; Fischer D. Neuromuscular Disorders. 2014.

Neurofibromatosis type 1 (NF1) with an unusually severe phenotype due to digeny for NF1 and ryanodine receptor 1 associated myopathy.

Martin F; Kana V; Mori AC; Fischer D; Parkin N; Boltshauser E; Rushing EJ; Klein A. European journal of pediatrics. 2014.

Skeletal muscle MRI of the lower limbs in congenital muscular dystrophy patients with novel POMT1 and POMT2 mutations.

Hafner P; Bonati U; Fischmann A; Schneider J; Frank S; Morris-Rosendahl DJ; Dumea A; Heinimann K; Fischer D. Neuromuscular Disorders. 2014.

Mutations at Ser331 in the HSN type I gene SPTLC1 are associated with a distinct syndromic phenotype.

Auer-Grumbach M; Bode H; Pieber TR; Schabhüttl M; Fischer D; Seidl R; Graf E; Wieland T; Schuh R; Vacariu G; Grill F; Timmerman V; Strom TM; Hornemann T. European Journal of Medical Genetics. 2013.

Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy.

Fischmann A; Hafner P; Gloor M; Schmid M; Klein A; Pohlman U; Waltz T; Gonzalez R; Haas T; Bieri O; Fischer D. Journal of Neurology. 2013.

Quinine sulfate as a therapeutic option in a patient with slow channel congenital myasthenic syndrome.

Peyer AK; Abicht A; Heinimann K; Sinnreich M; Fischer D. Neuromuscular Disorders. 2013.

Response to Wakerley et al. letter: Surgery itself does not trigger Guillain-Barré syndrome.

Gensicke H; Fischer D. European journal of neurology. 2013.

Exercise might bias skeletal-muscle fat fraction calculation from Dixon images.

Fischmann A; Kaspar S; Reinhardt J; Gloor M; Stippich C; Fischer D. Neuromuscular Disorders. 2012.

High resolution array in the clinical approach to chromosomal phenotypes.

Filges I; Suda L; Weber P; Datta AN; Fischer D; Dill P; Glanzmann R; Benzing J; Hegi L; Wenzel F; Huber AR; Mori AC; Miny P; Röthlisberger B. GENE. 2012.

Increased incidence of Guillain-Barré syndrome after surgery.

Gensicke H; Datta AN; Dill P; Schindler C; Fischer D. European journal of neurology. 2012.

Quantitative MRI can detect subclinical disease progression in muscular dystrophy.

Fischmann A; Hafner P; Fasler S; Gloor M; Bieri O; Studler U; Fischer D. Journal of Neurology. 2012.

Alterations of excitation-contraction coupling and excitation coupled Ca(2+) entry in human myotubes carrying CAV3 mutations linked to rippling muscle.

Ullrich ND; Fischer D; Kornblum C; Walter MC; Niggli E; Zorzato F; Treves S. Human mutation. 2011.

Enhanced excitation-coupled Ca(2+) entry induces nuclear translocation of NFAT and contributes to IL-6 release from myotubes from patients with central core disease.

Treves S; Vukcevic M; Jeannet PY; Levano S; Girard T; Urwyler A; Fischer D; Voit T; Jungbluth H; Lillis S; Muntoni F; Quinlivan R; Sarkozy A; Bushby K; Zorzato F. Human molecular genetics. 2011.

Muscle imaging in congenital myopathies.

Quijano-Roy S; Carlier RY; Fischer D. SEMIN PEDIATR NEUROL. 2011.

Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy.

Fischmann A; Gloor M; Fasler S; Haas T; Rodoni Wetzel R; Bieri O; Wetzel S; Heinimann K; Scheffler K; Fischer D. Journal of Neurology. 2011.

Normal muscle MRI does not preclude increased connective tissue in muscle of recessive myotonia congenita.

Hilbert P; Frank S; Raheem O; Suominen T; Penttilä S; Udd B; Fischer D. Acta neurologica Scandinavica. 2011.

Quantification of fat infiltration in oculopharyngeal muscular dystrophy: comparison of three MR imaging methods.

Gloor M; Fasler S; Fischmann A; Haas T; Bieri O; Heinimann K; Wetzel SG; Scheffler K; Fischer D. Journal of magnetic resonance imaging : JMRI. 2011.

SNP-array based whole genome homozygosity mapping: a quick and powerful tool to achieve an accurate diagnosis in LGMD2 patients.

Papić L; Fischer D; Trajanoski S; Höftberger R; Fischer C; Ströbel T; Schmidt WM; Bittner RE; Schabhüttl M; Gruber K; Pieber TR; Janecke AR; Auer-Grumbach M. European Journal of Medical Genetics. 2011.

Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy.

Kennerson ML; Nicholson GA; Kaler SG; Kowalski B; Mercer JF; Tang J; Llanos RM; Chu S; Takata RI; Speck-Martins CE; Baets J; Almeida-Souza L; Fischer D; Timmerman V; Taylor PE; Scherer SS; Ferguson TA; Bird TD; De Jonghe P; Feely SM; Shy ME; Garbern JY. American Journal of Human Genetics. 2010.

Neuromuscular imaging in inherited muscle diseases.

Wattjes MP; Kley RA; Fischer D. European radiology. 2010.

Reverse protein arrays as novel approach for protein quantification in muscular dystrophies.

Escher C; Lochmüller H; Fischer D; Frank S; Reimann J; Walter MC; Ehrat M; Ruegg MA; Gygax D. Neuromuscular Disorders. 2010.

How much mutant protein is needed to cause a protein aggregate myopathy in vivo? Lessons from an exceptional desminopathy.

Clemen CS; Fischer D; Reimann J; Eichinger L; Müller CR; Müller HD; Goebel HH; Schröder R. Human mutation. 2009.

Clinical, genetic, and cardiac magnetic resonance imaging findings in primary desminopathies.

Strach K; Sommer T; Grohé C; Meyer C; Fischer D; Walter MC; Vorgerd M; Reilich P; Bär H; Reimann J; Reuner U; Germing A; Goebel HH; Lochmüller H; Wintersperger B; Schröder R. Neuromuscular Disorders. 2008.

Distinct muscle imaging patterns in myofibrillar myopathies.

Fischer D; Kley RA; Strach K; Meyer C; Sommer T; Eger K; Rolfs A; Meyer W; Pou A; Pradas J; Heyer CM; Grossmann A; Huebner A; Kress W; Reimann J; Schröder R; Eymard B; Fardeau M; Udd B; Goldfarb L; Vorgerd M; Olivé M. Neurology. 2008.

Dynamin 2-related centronuclear myopathy: clinical, histological and genetic aspects of further patients and review of the literature.

Jeub M; Bitoun M; Guicheney P; Kappes-Horn K; Strach K; Druschky KF; Weis J; Fischer D. Clinical neuropathology. 2008.

Relative contribution of mutations in genes for autosomal dominant distal hereditary motor neuropathies: a genotype-phenotype correlation study.

Dierick I; Baets J; Irobi J; Jacobs A; De Vriendt E; Deconinck T; Merlini L; Van den Bergh P; Rasic VM; Robberecht W; Fischer D; Morales RJ; Mitrovic Z; Seeman P; Mazanec R; Kochanski A; Jordanova A; Auer-Grumbach M; Helderman-van den Enden AT; Wokke JH; Nelis E; De Jonghe P; Timmerman V. Brain : a journal of neurology. 2008.

Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients.

Kley RA; Hellenbroich Y; van der Ven PF; Fürst DO; Huebner A; Bruchertseifer V; Peters SA; Heyer CM; Kirschner J; Schröder R; Fischer D; Müller K; Tolksdorf K; Eger K; Germing A; Brodherr T; Reum C; Walter MC; Lochmüller H; Ketelsen UP; Vorgerd M. Brain : a journal of neurology. 2007.

Phenotypic patterns of desminopathy associated with three novel mutations in the desmin gene.

Olivé M; Armstrong J; Miralles F; Pou A; Fardeau M; Gonzalez L; Martínez F; Fischer D; Martínez Matos JA; Shatunov A; Goldfarb L; Ferrer I. Neuromuscular Disorders. 2007.

Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy.

Fischer D; Herasse M; Bitoun M; Barragán-Campos HM; Chiras J; Laforêt P; Fardeau M; Eymard B; Guicheney P; Romero NB. Brain : a journal of neurology. 2006.

Different early pathogenesis in myotilinopathy compared to primary desminopathy.

Fischer D; Clemen CS; Olivé M; Ferrer I; Goudeau B; Roth U; Badorf P; Wattjes MP; Lutterbey G; Kral T; van der Ven PF; Fürst DO; Vicart P; Goldfarb LG; Moza M; Carpen O; Reichelt J; Schröder R. Neuromuscular Disorders. 2006.

Variable pathogenic potentials of mutations located in the desmin alpha-helical domain.

Goudeau B; Rodrigues-Lima F; Fischer D; Casteras-Simon M; Sambuughin N; de Visser M; Laforet P; Ferrer X; Chapon F; Sjöberg G; Kostareva A; Sejersen T; Dalakas MC; Goldfarb LG; Vicart P. Human mutation. 2006.

Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs.

Fischer D; Walter MC; Kesper K; Petersen JA; Aurino S; Nigro V; Kubisch C; Meindl T; Lochmüller H; Wilhelm K; Urbach H; Schröder R. Journal of Neurology. 2005.

Hsp27-2D-gel electrophoresis is a diagnostic tool to differentiate primary desminopathies from myofibrillar myopathies.

Clemen CS; Fischer D; Roth U; Simon S; Vicart P; Kato K; Kaminska AM; Vorgerd M; Goldfarb LG; Eymard B; Romero NB; Goudeau B; Eggermann T; Zerres K; Noegel AA; Schröder R. FEBS Letters. 2005.

Myotilinopathy: refining the clinical and myopathological phenotype.

Olivé M; Goldfarb LG; Shatunov A; Fischer D; Ferrer I. Brain : a journal of neurology. 2005.

Pathogenic effects of a novel heterozygous R350P desmin mutation on the assembly of desmin intermediate filaments in vivo and in vitro.

Bär H; Fischer D; Goudeau B; Kley RA; Clemen CS; Vicart P; Herrmann H; Vorgerd M; Schröder R. Human molecular genetics. 2005.

On the early diagnosis of IVIg-responsive chronic multifocal acquired motor axonopathy.

Fischer D; Grothe C; Schmidt S; Schröder R. Journal of Neurology. 2004.

Consequences of a novel caveolin-3 mutation in a large German family

Fischer, D; Schroers, A; Blumcke, I; Urbach, H; Zerres, K; Mortier, W; Vorgerd, M; Schroder, R. Annals of neurology. 2003.

On noxious desmin: functional effects of a novel heterozygous desmin insertion mutation on the extrasarcomeric desmin cytoskeleton and mitochondria.

Schröder R; Goudeau B; Simon MC; Fischer D; Eggermann T; Clemen CS; Li Z; Reimann J; Xue Z; Rudnik-Schöneborn S; Zerres K; van der Ven PF; Fürst DO; Kunz WS; Vicart P. Human molecular genetics. 2003.

On symptomatic heterozygous alpha-sarcoglycan gene mutation carriers.

Fischer D; Aurino S; Nigro V; Schröder R. Annals of neurology. 2003.

Expression, localization and functional divergence of alphaB-crystallin and heat shock protein 27 in core myopathies and neurogenic atrophy.

Fischer D; Matten J; Reimann J; Bönnemann C; Schröder R. Acta Neuropathologica. 2002.

Granulomatous myositis associated with antithyroglobulin and antithyroid peroxidase antibodies: an analogy to Hashimoto's encephalitis?

Fischer D; Schröder R. Journal of Neurology. 2002.